PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance
Vivek Verma(Georgetown University), Rajeev Shrimali(The University of Texas MD Anderson Cancer Center), Shamim Ahmad(Five Prime Therapeutics (United States)), Winjie Dai(Augusta University Health), Hua Wang(Augusta University Health), Sumin Lu(Augusta University Health), Rahul Nandre(Georgetown University), Pankaj Gaur(Georgetown University), J. Alejandro López(Georgetown University), Moshe Sade-Feldman(Broad Institute), Keren Yizhak(Broad Institute), Stacey L. Bjorgaard(Broad Institute), Keith T. Flaherty(Massachusetts General Hospital), Jennifer A. Wargo(The University of Texas MD Anderson Cancer Center), Genevieve M. Boland(Massachusetts General Hospital), Ryan J. Sullivan(Massachusetts General Hospital), Gad Getz(Broad Institute), Scott A. Hammond, Ming Tan(Georgetown University), Jingjing Qi(Memorial Sloan Kettering Cancer Center), Phillip Wong(Memorial Sloan Kettering Cancer Center), Taha Merghoub(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Memorial Sloan Kettering Cancer Center), Nir Hacohen(Broad Institute), John E. Janik(Augusta University Health), Mikayel Mkrtichyan(Georgetown University), Seema Gupta(Georgetown University), Samir N. Khleif(Georgetown University)
Cited by 333Open Access
Abstract
Related Papers
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
Yoshiko Iwai, Masayoshi Ishida, Yoshimasa Tanaka et al.|Proceedings of the National Academy of Sciences|2002|3.2k